Avastin (bevacizumab) / Roche - LARVOL DELTA

Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial. (PubMed, Nat Commun) - P2 | "QoL significantly improved from baseline at 12 months and was maintained through 36 months. These findings support the efficacy and safety of alectinib plus bevacizumab and justify further investigation in ALK-rearranged NSCLC."

Journal • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Disease • Solid Tumor • ALK

Seminal Abstract: TRUST: TRIAL OF RADICAL UPFRONT SURGICAL THERAPY IN ADVANCED OVARIAN CANCER (ENGOT OV33/AGO‐OVAR OP7) (IGCS 2025) - "Maintenance treatment with bevacizumab and/or PARP inhibitors was allowed if selection criteria was similar for both arms... In expert centers with proven surgical quality, PCS followed by iv chemotherapy resulted in a significantly longer median PFS and a numerically longer OS compared to NACT/ICS in non-frail OC pts. Although statistical significance in the primary endpoint was not reached, this is the first randomized trial to show a benefit of PCS over ICS. This benefit is likely to be associated with the high complete resection rate, reinforcing PCS as a standard of care in non-frail pts with seemingly resectable advanced OC."

Metastases • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor

PEMBROLIZUMAB VS PLACEBO PLUS PACLITAXEL ± BEVACIZUMAB FOR PLATINUM-RESISTANT RECURRENT OVARIAN CANCER: RESULTS FROM THE PHASE 3 ENGOTOV65/KEYNOTE-B96 STUDY (IGCS 2025) - P3 | "Efficacy results favored the pembrolizumab arm (Table 1). Subsequent anticancer therapies were used by 52.2% and 60.4% in the pembrolizumab and placebo arms, respectively (Table 2). Grade ≥3 treatment-related adverse events occurred in 67.5% vs 55.3%, respectively."

Clinical • Late-breaking abstract • P3 data • Platinum resistant • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • PD-L1

BREAKWATER: Primary analysis of first-line (1L) encorafenib + cetuximab (EC) + FOLFIRI in BRAF V600E-mutant metastatic colorectal cancer (mCRC). (ASCO-GI 2026) - P3 | "Background: Leucovorin/5-FU in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are common chemotherapies used in 1L mCRC. In patients (pts) with BRAF V600E-mutant mCRC, the Phase 3 portion of BREAKWATER (NCT04607421) demonstrated clinically meaningful and statistically significantly improved ORR by blinded independent central review (BICR), PFS by BICR, and OS with 1L EC + mFOLFOX6 vs chemotherapy ± bevacizumab (bev) (Kopetz Nat Med 2025; Elez N Engl J Med 2025)... BREAKWATER Cohort 3 demonstrated a clinically meaningful and statistically significant improved response rate that was rapid and durable with EC+FOLFIRI vs control in 1L BRAF V600E-mutant mCRC, with manageable toxicities and no new safety signals. These data support EC+FOLFIRI as a potential new standard of care in BRAF V600E-mutant mCRC. aBy BICR."

Clinical • Metastases • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • BRAF

Liver resection after atezolizumab and bevacizumab versus maintenance therapy for locally advanced hepatocellular carcinoma (TALENTOP): a multicentre, open-label, randomised, phase 3 trial. (PubMed, Lancet) - P3 | "In patients with advanced hepatocellular carcinoma with macrovascular invasion after systemic therapy, time to treatment failure was longer in those who had liver resection than in those who received maintenance therapy."

Clinical • Journal • P3 data • Hepatocellular Cancer • Hepatology • Liver Failure • Oncology • Renal Disease • Solid Tumor

Pembrolizumab Plus Chemotherapy for Cervical Cancer: An Exploratory Analysis of the KEYNOTE-826 Randomized Clinical Trial. (PubMed, JAMA Oncol) - P3 | "In this exploratory analysis of the KEYNOTE-826 randomized clinical trial, the 5-year data confirm the durability of benefit and reinforce pembrolizumab plus chemotherapy (with or without bevacizumab) as a first-line standard-of-care option for recurrent and metastatic cervical cancer. ClinicalTrials.gov Identifier: NCT03635567."

Clinical • Journal • Cervical Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • PD-L1

Optimal First-Line Therapy Selection for Metastatic Colorectal Cancer (IASGO 2026) - "For most patients with pMMR/MSS tumors, a fluoropyrimidine-based doublet remains the backbone.FOLFOX and FOLFIRI provide similar efficacy, so the choice should reflect comorbidities andanticipated toxicity: neuropathy and thrombocytopenia are more relevant with oxaliplatin, whereasgastrointestinal toxicity and alopecia are more common with irinotecan...In left-sided RAS/BRAF wild-type mCRC,cetuximab plus FOLFOX or FOLFIRI is an appropriate first-line strategy...Three clinical cases illustrate this framework: a left-sided RAS/BRAF wild-type MSS tumor treated withcetuximab-FOLFIRI; a right-sided MSS tumor treated with bevacizumab-FOLFOX; and an MSI-H cecalcancer achieving a deep response to pembrolizumab. The central message is that first-line therapyshould follow a structured sequence: profile the tumor, define treatment goals and fitness, match thebiologic strategy, and apply current Korean reimbursement criteria while preserving effective optionsfor later lines."

Clinical • IO biomarker • Metastases • Alopecia • Colorectal Cancer • Immunology • Microsatellite Instability • Oncology • Solid Tumor • Thrombocytopenia • BRAF • KRAS • MSI • NRAS • POLD1 • POLE

The Advanced Lung Cancer Inflammation Index as a Prognostic Indicator in Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy (IASGO 2026) - "Subgroup analyses showed that the trend toward improved outcomes was consistent for high ALIvalues in all clinically relevant subgroups. Conclusions : High pretreatment ALI independently predicted improved survival outcomes and mayserve as a simple and readily available prognostic biomarker for risk stratification in u-HCC patientsreceiving Atez/Be."

Biomarker • Clinical • Metastases • Hepatocellular Cancer • Lung Cancer • Oncology • Solid Tumor

Systemic Therapy as an Enabler: From Disease Control to Curative Intent (IASGO 2026) - "A China phase 2 randomised-controlled trial on adjuvant immune checkpoint inhibitordemonstrated an improved recurrence-free survival of HCC patients with microvascular invasion, butthe results were not reproduced in IMbrave050 and KEYNOTE-937 on atezolizumab and bevacizumab,and pembrolizumab, respectively. This lecture will present an overview of current and future therapeutic options and treatment strategiesas adjuvant and pre/perioperative treatment for resectable HCC. Case illustration will also be providedto show evidence in the real-world setting."

Hepatocellular Cancer • Solid Tumor

Impact of Liver Disease Etiology on Outcomes of Atezolizumab–Bevacizumab in Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study (IASGO 2026) - "Conclusions : In this large real-world multicenter cohort, atezolizumab plus bevacizumabdemonstrated comparable efficacy across viral and non-viral etiologies of uHCC. Treatment outcomeswere primarily driven by liver function, performance status, and tumor burden rather than by underlyingetiology."

Clinical • Metastases • Real-world • Real-world evidence • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Oncology • Solid Tumor

Hepatectomy after Systemic Treatment (IASGO 2026) - "Systemic therapy for unresectable hepatocellular carcinoma (HCC) has advanced substantially sincethe introduction of atezolizumab plus bevacizumab and subsequent immune checkpoint inhibitor-based combinations. However realizing thisbenefit in practice depends on disciplined attention to perioperative process — particularlybevacizumab washout timing, reassessment of hepatic functional reserve after systemic therapyexposure, and multidisciplinary, response-driven decision-making together with vigilant, biologicallyappropriate postoperative surveillance. As this strategy matures, the surgeon's role within themanagement of advanced HCC will be expanded correspondingly."

Hepatocellular Cancer • Solid Tumor

Clinical Significance of Nutritional Factors in Conversion Surgery for HCC (IASGO 2026) - "We retrospectively analyzed 163 patients with advanced HCC treated with atezolizumab plusbevacizumab or durvalumab plus tremelimumab. Preserving nutritional status may help patientsmaintain treatment tolerance, liver function, and physical reserve until resectability is achieved.However, this retrospective study does not establish that nutritional intervention itself increases thelikelihood of CS or improves survival. Prospective studies incorporating nutritional assessment andintervention are needed to define the role of peri-treatment nutritional management in conversionstrategies for HCC."

Clinical • Surgery • Hepatocellular Cancer • Solid Tumor

Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting ➔ Recruiting

Enrollment open • Colorectal Cancer • Oncology • Solid Tumor

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of SYS6043 ± Bevacizumab ± Chemotherapy in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=400 | Not yet recruiting | Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.

New P1/2 trial • Oncology • Ovarian Cancer • Solid Tumor • BRCA • BRCA1 • BRCA2 • MUC16

RMC-GI-102: Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors (clinicaltrials.gov) - P1/2 | N=1130 | Recruiting | Sponsor: Revolution Medicines, Inc. | Trial completion date: Jul 2027 ➔ Mar 2030 | Trial primary completion date: May 2027 ➔ Sep 2028

Trial completion date • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • RAS

HEC-921 Injection as Monotherapy and in Combination With Antineoplastic Therapies in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=110 | Not yet recruiting | Sponsor: Sunshine Lake Pharma Co., Ltd.

Monotherapy • New P1 trial • Colon Adenocarcinoma • Colon Cancer • Oncology • Rectal Adenocarcinoma • Solid Tumor • LY6G6D

Phase I/II Study of Nilvanstomig (ZG005) Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment for Advanced Cervical Cancer: Updated Results of Efficacy and Safety (ESMO 2026) - No abstract available

Clinical • Metastases • P1/2 data • Cervical Cancer • Oncology • Solid Tumor

ARTEMIDE-HCC01: Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma (clinicaltrials.gov) - P3 | N=1220 | Recruiting | Sponsor: AstraZeneca | Trial primary completion date: Mar 2029 ➔ Mar 2030

IO biomarker • Trial primary completion date • Hepatocellular Cancer • Oncology • Solid Tumor • PD-L1

Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. (PubMed, J Clin Oncol) - "Navicixizumab plus paclitaxel demonstrated promising clinical activity in bevacizumab-treated and -naive patients with platinum-resistant ovarian cancer, with manageable toxicity."

Journal • P1 data • Fallopian Tube Cancer • Hematological Disorders • Hypertension • Neutropenia • Oncology • Ovarian Cancer • Pulmonary Arterial Hypertension • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Thrombocytopenia

ZG005 Plus Bevacizumab vs Sintilimab Plus Bevacizumab as First-Line Therapy for Advanced Hepatocellular (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd

New P3 trial • Hepatocellular Cancer • Oncology • Solid Tumor

Tumor dynamic model-based decision support for Phase Ib/II combination studies: A retrospective assessment based on resampling of the Phase III study IMpower150. (PubMed, Clin Cancer Res) - "Model-based estimate of KG GMR is an exploratory endpoint that informs early clinical decisions for combination studies."

Journal • P1/2 data • P3 data • Retrospective data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer. (ASCO 2023) - P2, P3 | "Approximately 400 patients will be randomized 1:1 to the TUC experimental arm (TUC [300 mg orally twice daily] + Tras + mFOLFOX) or the SOC arm (mFOLFOX alone or in combination with either bevacizumab or cetuximab)...Enrollment is ongoing in North America, Asia, Australia, and Europe. Clinical trial information: NCT05253651."

Clinical • Metastases • P3 data • Breast Cancer • Colorectal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gastrointestinal Disorder • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • BRAF • HER-2

Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study. (PubMed, J Clin Oncol) - "This GOG-0218 trial investigation validates ICON-7 findings about the association between poor tumor chemosensitivity and benefit from concurrent-maintenance bevacizumab, suggesting that bevacizumab may mainly be effective in patients with poorly chemosensitive disease. Bevacizumab may be prioritized in patients with a high-risk and poorly chemosensitive disease to improve their PFS/OS (patient KELIM score calculator available on the Biomarker Kinetics website)."

Journal • Oncology • Ovarian Cancer • Solid Tumor

Effect of liver function on clinical outcomes in patients with unresectable hepatocellular carcinoma treated with first-line atezolizumab-bevacizumab: an Asia-Pacific multicenter retrospective analysis. (PubMed, Ann Hepatol) - "Liver function is a key prognostic factor in patients with uHCC treated with atezo-bev. These findings highlight the need to assess liver function when selecting systemic therapy and support further studies, including patients with impaired liver function."

Clinical data • Journal • Retrospective data • Hepatocellular Cancer • Oncology • Solid Tumor

Efficacy and safety of sacituzumab tirumotecan (sac-TMT) plus pembrolizumab in patients with recurrent or metastatic cervical cancer (ESMO 2024) - P2 | "Sac-TMT (also known as MK-2870/ SKB264) is a TROP2 ADC developed with novel linker to conjugate a belotecan-derivative topoisomerase I inhibitor...47.4% had received two prior lines of therapy, 52.6% had received bevacizumab, and 42.1% had received anti-PD-1 based therapy... Sac-TMT plus pembrolizumab demonstrated promising and durable antitumor activity with manageable safety profile. No new safety signal was observed. Considering the activity of this combination among pts who were pre-treated with anti-PD-1 based therapy, further investigation is warranted."

Clinical • Metastases • Cervical Cancer • Oncology • Solid Tumor